Stryker Corporation $SYK Stock Position Cut by Clearstead Trust LLC

Clearstead Trust LLC lessened its stake in Stryker Corporation (NYSE:SYK) by 30.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,544 shares of the medical technology company’s stock after selling 4,147 shares during the quarter. Clearstead Trust LLC’s holdings in Stryker were worth $3,354,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter valued at about $27,000. CGC Financial Services LLC bought a new position in shares of Stryker during the 4th quarter valued at about $29,000. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter valued at about $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the 3rd quarter valued at about $34,000. Finally, Copia Wealth Management boosted its position in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $316.39 on Monday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a 50-day moving average of $325.22 and a two-hundred day moving average of $349.76. The stock has a market cap of $121.29 billion, a price-to-earnings ratio of 36.62, a PEG ratio of 1.99 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business earned $2.84 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SYK. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. UBS Group reduced their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Evercore set a $355.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, William Blair restated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $395.48.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 4.60% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.